If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.00    0.00 (0.00%)
Bid:
27.00
Ask:
29.00
Spread: 2.00 (7.407%)
Market Cap: £74.17m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Directorate Change

3 Jun 2013 07:00

RNS Number : 0304G
Maven Income and Growth VCT 5 PLC
03 June 2013
 



 

Maven Income and Growth VCT 5 PLC

 

Directorate Changes

 

The Board of Maven Income and Growth VCT 5 PLC is pleased to announce the appointment of Mr Allister Langlands and Mr Charles Young as Non-executive Directors with effect from 1 June 2013. Mr Langlands and Mr Young will also both serve on the Company's Audit, Management Engagement, Nomination and Remuneration Committees.

 

Mr Langlands is Chairman of John Wood Group PLC, having served as chief executive from 2007 to 2012 and previously as deputy chief executive from 1999 and as group finance director from 1991.

 

Allister has an MA (Hons) in Economics from the University of Edinburgh and completed the Harvard Advanced Management Program in 1999. He is also a member of the Institute of Chartered Accountants of Scotland, having trained with Deloitte Haskins & Sells (now PricewaterhouseCoopers) before being made a partner in 1989.

 

Mr Young is chief executive of E G Thomson (Holdings) Limited, a private investment company. He is also a non-executive director of Ben Line Agencies Limited and Exakt Precision Tools Limited, and his recent former directorships include Minoan Group Plc.

 

Charles is a Bachelor of Laws and is a member of the Institute of Chartered Accountants of Scotland, having trained with Arthur Young McClelland Moores & Co (now part of Ernst & Young). He was employed by The British Linen Bank Limited between 1979 and 1997, serving as a main board director from 1991 until 1997, as a director of its corporate finance division from 1986 to 1992 and as managing director of its private equity operations from 1992 to1997.

 

In relation to either of these appointments, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

 

These appointments are part of a succession plan, announced on 18 March 2013, for which the Board has considered a number of candidates with the intention that one or more of the then Directors would step down between the Annual General Meetings to be held in 2013 and 2014 in order to allow new Board members to be appointed. Each new Director will be subject to re-election by Shareholders at the first Annual General Meeting following their appointment and confirmation of any further changes to the constitution of the Board will be communicated fully to Shareholders in due course.

 

Maven Capital Partners UK LLP

Secretary

3 June 2013

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFFLFXXEFEBBE
Date   Source Headline
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
21st Mar 20254:35 pmRNSNet Asset Value(s)
12th Mar 20254:54 pmRNSAnnual Financial Report
26th Feb 20254:41 pmRNSTransaction in Own Shares
26th Feb 202510:33 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:12 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
17th Dec 20243:27 pmRNSDirectorate Change
13th Dec 20242:45 pmRNSUnaudited Net Asset Value
14th Nov 20242:58 pmRNSResult of General Meeting
8th Oct 20245:01 pmRNSTransaction in Own Shares
4th Oct 20244:18 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 20249:47 amRNSIssue of Equity
5th Sep 20242:28 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:36 pmRNSUnaudited Net Asset Value
12th Jul 20244:37 pmRNSTransaction in Own Shares
12th Jul 20244:09 pmRNSHalf-year Report
10th Jul 20245:05 pmRNSTransaction in Own Shares
5th Jul 202412:38 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
9th May 20244:05 pmRNSTransaction in Own Shares
3rd May 20249:28 amRNSIssue of Equity
1st May 202410:10 amRNSIssue of Equity
26th Apr 20242:44 pmRNSUnaudited NAV - Dividend Investment Scheme
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares
21st Jul 20239:48 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.